NL-OMON31421已完成3 期
An open-label, randomised, comparative, multi-centre study of the immunogenicity and safety of a 1-dose regimen and different 2-dose regimens of a Zoster vaccine (Live), ZOSTAVAX, in subjects >= 70 years of age - Zostavax-study
Sanofi Pasteur MSD S.N.C.0 个研究点目标入组 150 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •70 years or older, varicella history-positive or residence for > 30 years in a country with endemic VZV infection
排除标准
- •Febrile within the last 72 hours before vaccination, history of hypersensitivity/anaphylactoid reaction to ZOSTAVAX components including gelatine or neomycin, prior herpes-zoster episode clinically diagnosed by a physician
研究者
相似试验
进行中（未招募）
不适用
An open-label, randomised, comparative, multi-centre study of the immunogenicity and safety of a 2-dose regimen of ProQuad® manufactured with rHA administered to healthy children from 9 months of ageMeasles, mumps, rubella and varicella vaccine administered to healthy children from 9 months of ageEUCTR2007-002468-88-FISanofi Pasteur MSD SNC1,620
进行中（未招募）
1 期
An open-label, randomised, comparative, multi-centre study of the immunogenicity and safety of a 1-dose regimen and different 2-dose regimens of a Zoster vaccine (Live), ZOSTAVAX ®, in subjects = 70 years of ageEUCTR2007-000744-28-NLSanofi Pasteur MSD S.N.C.
进行中（未招募）
不适用
An open-label, randomised, comparative, multi-centre study of the immunogenicity and safety of a 2-dose regimen of ProQuad® manufactured with rHA administered to healthy children from 9 months of ageMeasles, mumps, rubella and varicella vaccine administered to healthy children from 9 months of ageEUCTR2007-002468-88-DESanofi Pasteur MSD SNC1,620
进行中（未招募）
不适用
An open-label, randomised, comparative, multi-centre study of the immunogenicity and safety of a 1-dose regimen and different 2-dose regimens of a Zoster vaccine (Live), ZOSTAVAX , in subjects equal or over 70 years of age - NDEUCTR2007-000744-28-ITSanofi Pasteur MSD S.N.C.750
进行中（未招募）
不适用
An open-label, randomised, comparative, multi-centre study of the immunogenicity and safety of the concomitant use of a live pentavalent rotavirus vaccine (RotaTeq®) and a meningococcal group C conjugate (MCC) vaccine in healthy infantsRotaTeq® is indicated for the active immunisation of infants from age of 6 weeks for prevention of gastroenteritis due to rotavirus infection.NeisVac-C® is indicated for active immunisation of children from 2 months of age for the prevention of invasive disease caused by Neisseria meningitidis serogroup CEUCTR2006-005445-11-FISanofi Pasteur MSD S.N.C.